Description:

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients https://clinicaltrials.gov/ct2/show/NCT00099502 The purpose of this study is to determine - whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms - whether treatment with Betaferon / Betaseron (interferon beta-1b) tolerable and more efficacious than treatment with Copaxone (Glatiramer Acetate) 20 mg

Link:
https://clinicaltrials.gov/ct2/show/NCT00099502
Keywords:
  1. 12/11/13 12/11/13 - Martin Dugas
  2. 8/21/15 8/21/15 - Martin Dugas
Uploaded on:

August 21, 2015

DOI:
To request one please log in.
License :
Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Multiple Sclerosis Betaferon/Betaseron NCT00099502

Eligibility Multiple Sclerosis Betaferon/Betaseron NCT00099502

Einschlusskriterien
Gender
Age
RRMS
EDSS score
Treatment
Ausschlusskriterien
Neurological progression
heart diseases
Severe depression
dysfunctions
Monoclonal gammopathy
Allergies
Pregnancy or lactation
Medizinische Konzepte

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial